These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17178666)

  • 1. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
    Buckstein R; Patel H; Chesney A; Reis M; Imrie K
    Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
    Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
    Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases.
    Hoffman MA
    Med Oncol; 2011 Dec; 28(4):1537-41. PubMed ID: 20509009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
    Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I
    Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
    Nieva J; Bethel K; Saven A
    Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
    Quach H; Januszewicz H; Westerman D
    Haematologica; 2005 Nov; 90 Suppl():ECR26. PubMed ID: 16266917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
    Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
    Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine.
    Hoffman M; Auerbach L
    Br J Haematol; 2000 Jun; 109(4):900-1. PubMed ID: 10970137
    [No Abstract]   [Full Text] [Related]  

  • 9. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
    Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
    Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia.
    Hagberg H
    Med Oncol; 1999 Sep; 16(3):221-2. PubMed ID: 10523804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
    Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M
    Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment of refractory hairy cell leukemia with rituximab].
    Onaka T; Ozumi N; Yonezawa A; Imada K
    Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1987-9. PubMed ID: 19764485
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
    Pollio F; Pocali B; Palmieri S; Morabito P; Scalia G; Del Vecchio L; Ferrara F
    Ann Hematol; 2002 Dec; 81(12):736-8. PubMed ID: 12483372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
    Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
    Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of hairy cell leukemia variant with rituximab.
    Narat S; Gandla J; Dogan A; Mehta A
    Leuk Lymphoma; 2005 Aug; 46(8):1229-32. PubMed ID: 16085567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
    Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
    Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).
    Zenhäusern R; Simcock M; Gratwohl A; Hess U; Bargetzi M; Tobler A;
    Haematologica; 2008 Sep; 93(9):1426-8. PubMed ID: 18603561
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.
    Hagberg H; Lundholm L
    Br J Haematol; 2001 Dec; 115(3):609-11. PubMed ID: 11736943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
    Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
    Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
    [No Abstract]   [Full Text] [Related]  

  • 20. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.